»

[Etiennester]

I'm glad you all bought when I tagged it as a screaming buy and insisted at 1.30 . lol.

I sold out at 3.13, but I'm waiting to buy back on a pullback towards 2.20 if it happens. I think there are odds of dilution so I'm not willing to take any risks holding in the 2.80+ zone. I also think there are odds of a buyout so I'm willing to buy under 2.50

Thought I think it's going to be less volatile from here, the potential target stays 5.00 within January. But to me it's not a high enough reward/risk ratio and I see better companies out there at this point in time. Also, buying anything in this overbought market is not compelling at all.

For value-keeping and y.o.y growth, this is a great investment and should do a ILMN type of move (2003-2006) if it's not bought out very fast. This is a rewarding situation in any case if you're ready to wait the years and buy more on dips. But like I said, downside is 2.20, because of a possible common share offering or a stock market pullback.

[GregTheGreatONE]

Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement

CAMBRIDGE, Mass., Sep 16, 2009 (BUSINESS WIRE) -- Helicos BioSciences Corporation (HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive agreement with certain new and existing investors, including Atlas Ventures, Flagship Ventures, Highland Capital Partners, Versant Ventures (the "Existing Investors") and Ron Lowy, the Company's chief executive officer, to raise approximately $10 million in gross proceeds in a private placement through the sale of shares of its common stock and warrants. The Company estimates that net proceeds from the offering will be approximately $9.4 million, after deducting placement agent fees and estimated offering expenses, which Helicos intends to use to fund working capital requirements to support its sales and for general corporate purposes.

"We believe that raising this level of funds is appropriate given the recent demand for the Helicos(TM) Single Molecule Sequencing System while we consider our strategic alternatives" said Ron Lowy, the Company's Chief Executive Officer.

Helicos has entered into a securities purchase agreement pursuant to which it has agreed to sell an aggregate of up to 1,030,028 units for $2.57 per unit to the Existing Investors and 3,281,252 units to new investors for $2.24 per unit. The units purchased by the Existing Investors will consist of one share of the Company's common stock and one warrant to purchase 0.662 shares of the Company's common stock at a per share exercise price equal to $2.61 (105% of the closing bid price of the Company's common stock on September 15, 2009). The units purchased by the new investors will consist of one share of the Company's common stock and one warrant to purchase 0.50 shares of the Company's common stock at a per share exercise price of $2.61. Units will not be issued or certificated. The shares of common stock and the warrants are immediately separable and will be issued separately, but will be purchased together in this offering. The warrants will have a five and a half year term and include a six-month "lock-up" provision, meaning that they will not be exercisable until six months following the closing of the transaction. The closing of the transaction is expected to occur on or about September 18, 2009, subject to the satisfaction of customary closing conditions. Thomas Weisel Partners LLC acted as exclusive placement agent for the offering.

In connection with the private placement, the Company entered into a registration rights agreement with each of the investors. The registration rights agreement provides that the Company will file a "resale" registration statement covering all of the shares of common stock issued to the investors and the shares issuable to them upon exercise of the warrants, up to the maximum number of shares permitted to be registered under the federal securities laws. The Company is required to file the registration statement within 15 days of the closing of the private placement. If any shares are unable to be included on the initial registration statement, the Company has agreed to file subsequent registration statements until all the shares have been registered, and the registration rights agreement imposes certain customary cash penalties on the Company for its failure to satisfy specified filing and effectiveness time periods.

The units to be issued in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from the registration requirements of the Securities Act. The units were offered and are being sold only to a limited number of accredited investors.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Helicos BioSciences:

Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos' proprietary True Single Molecule Sequencing, tSMS(TM), technology allows direct measurement of billions of strands of DNA enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of the $1,000 genome grant and committed to providing scientists the tools to unlock the era of genomic medicine. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800. For more information, please visit .

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the Company's ability to close the private placement, management's forecast of financial performance, estimates of expenses and future revenues and profitability, product development and marketing plans, and management's plans, objectives and strategies. These statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties, many of which are beyond Helicos' control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, our ability to successfully scale the manufacturing process and commercialize the HeliScope system; our history of operating losses and ability to achieve profitability; our ability to establish manufacturing capabilities; the research and development spending levels of academic, clinical and governmental research institutions and pharmaceutical, biotechnology and agriculture companies who may purchase our HeliScope system; our reliance on third-party suppliers; competition; changing technology and customer requirements; our ability to operate in an emerging market; market acceptance of our technology; the length of our sales and implementation cycles; our dependence on large contracts for the sale and implementation of our HeliScope system; failure of our technology and products; our ability to maintain customer relationships and contracts; ethical, legal and social concerns surrounding the use of genetic information; our ability to retain our personnel and hire additional skilled personnel; our ability to manage our rapid growth; our ability to obtain capital when desired on favorable terms; and the volatility of the market price of our common stock. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Helicos undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Helicos, see the disclosure contained in Helicos' public filings with the Securities and Exchange Commission.

[Etiennester]

It gave me a chance to buy back lower. It's nuts, most of the stocks I'm watching are diluting ASAP and as much as possible.

Insiders are selling.

Stock buybacks broke record lows on the S&P 500, down 86% from same quarter in 2008.

My biggest investment, VGZ, is screwing me with a 25% dilution at 10% premium. Even with gold running today, I'm stuck in the red with it.

Looks like mighty risky to buy anything in the stock market from up here.

[GregTheGreatONE]

ya im buying in again too after this one, i bought this stock at 1.30, and at 2.30 its still a good buy i always wanted to buy more, this is the time to do that definately (well unless u already got enough in already, which in my case i did but im greedy and want more...)

[george192002]

Im fairly new at this, so i was just wondering what makes you say that now is a good time to buy? It been going down the past few days. Does the chart say something?

I have read the previous posts but I am still cluless at the moment. No pun intended, i just want to know how you guys make your decisions.

[GregTheGreatONE]

..this stock will go up eventually, theres always a risk involved in any stock but i perfer to buy companys show promise in what they offer...their product is revolutionary, and the stock just got lower because they asked their major shareholders to sell high and rebuy low (to also promise they'll hold it for 5 years) , so now we can sneak in and buy some more shares while its back down again


http://www.helicosbio.com/Portals/0/..._SalesSpec.pdf

[george192002]

Thanks, i just got in at 2.28. Hope this goes back up.

[Miles]

Originally Posted by victor420 I am in a lot of green with this stock, not sure which way it will go from here. Will it be a stupid move to sell it now before the conference? Any thoughts are thoroughly appreciated!!!

Great stock, great company. FWIW, I am LONG on HLCS. Still holding from $1.39. Its given some back recently but all the more reason to hang on until the conference, and beyond IMO. Like the poster above says the product is a pretty big deal.

Etiennester: HLCS is approaching your stated rebuy zone of $2.20. Was curious if you will you be trading this one again?

[pdtpatrick]

Well their income statement sucked. Good thing their Assets to Liability looks good so thats a good outlook for the future.

But in looking at the 9 month charts, This is way up there, trading above 200 and 50 MA. Looks likes its pulling back as I expected. The major break out for these guys to seemed to have happened around 1.50 so im gonna set an alert if or when they start trading below 1.90. Then i'd be interested.

This is my first instinct, but maybe i'll change my mind later when I do further research with management and their current goals.

[george192002]

Helicos Presents at Cold Spring Harbor Laboratories Personal Genomes and CHI Next Generation Sequencing Meetings

CAMBRIDGE, Mass., Sep 22, 2009 (BUSINESS WIRE) -- Helicos BioSciences Corporation
(HLCS) provided updates on recent scientific findings and progress on Helicos's
technology initiatives.

Speaking at the Personal Genomes conference in Cold Spring Harbor, NY, and the
CHI Next Generation Sequencing conference in Providence, RI, Patrice Milos, Ph.D.
Vice President and Chief Scientific Officer provided an overview of recent
technological and scientific initiatives underway at Helicos.

Milos described projects the company undertook in collaboration with
world-renowned institutions such as the RIKEN institute in Japan and the Leiden
University Medical Center in the Netherlands. Both projects leveraged Helicos's
True Single Molecule Sequencing (tSMS)(TM) approach to obtain results previously
difficult or impossible to achieve with amplification-based sequencing
technologies.

The presentations also provided an update of Helicos's research and development
technology initiatives -- including a consumables improvement path designed to
provide multi-fold improvements to the Helicos(TM) Genetic Analysis System's
throughput with no changes to the instrument hardware.

Further, Milos described a series of revolutionary single-molecule-only methods
under development, which are designed to enable novel forms of genetic analysis
including:

-- library-free paired-reads with insert sizes in the range of 1 kilobase or
greater

-- methods for the analysis of picogram amounts of DNA without amplification

-- and the direct sequencing of RNA, without the generation of cDNA
intermediates.

These methods stem from the Helicos System's unique ability to detect and
sequence single molecules of DNA and RNA directly, freeing researchers from the
constraints of amplification, ligation and other complex sample preparation
techniques.

Copyright Business Wire 2009